SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th

Rhea-AI Summary

SELLAS Life Sciences Group (NASDAQ: SLS) announced that its CEO, Angelos Stergiou, will participate in the Cantor Oncology, Hematology, HemeOnc Conference on September 28, 2022, in New York City. Dr. Stergiou will be featured in the ‘Leukemia and MDS’ panel at 3:25 p.m. ET. SELLAS focuses on developing innovative therapies for various cancer types, with its lead candidate, GPS, targeting the WT1 protein associated with multiple tumors. The company also develops GFH009, a selective CDK9 inhibitor.

NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

Dr. Stergiou will participate in the ‘Leukemia and MDS’ panel at 3:25 p.m. Eastern Time.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

Any statements in this press release or made during the investor conference referenced herein about SELLAS’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact
Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com  
Phone: 212.896.1267

Media Contact
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
Email: SELLAS@kcsa.com  
Phone: 212.896.1204

FAQ

When is the Cantor Oncology Conference where SELLAS will be presenting?

The Cantor Oncology Conference will be held on September 28, 2022.

Who is representing SELLAS at the Cantor Oncology Conference?

Angelos Stergiou, CEO of SELLAS, will represent the company at the conference.

What is the focus of SELLAS Life Sciences Group?

SELLAS focuses on developing novel therapies for a broad range of cancer indications.

What is the significance of the GPS therapy developed by SELLAS?

GPS targets the WT1 protein and has potential as a treatment for various hematologic malignancies and solid tumors.

What time will Dr. Stergiou's panel discussion occur at the conference?

Dr. Stergiou's panel discussion will take place at 3:25 p.m. Eastern Time.